Search

Lymphoma experts Anas Younes, MD and Andrew Zelenetz, MD, PhD discuss the fast evolving research on CAR T cells and checkpoint inhibitors that is yielding the novel treatment options improving both outcomes and quality of life for people with lymphoma.

… Wednesday, May 16, 2018 VIDEO | 05:17 Lymphoma Update: CAR T Therapies and Checkpoint Inhibitors Lymphoma experts Anas Younes, MD and Andrew Zelenetz, MD, PhD discuss the fast evolving research on CAR T cells and checkpoint inhibitors that is yielding the novel treatment options improving both outcomes

A new MSK-led study used single-cell sequencing and other techniques to examine a phenomenon known as “whole-genome doubling” in high-grade serous ovarian carcinoma (HGSOC), the most common and aggressive form of ovarian cancer. The insights could help researchers develop more effective treatment strategies.

… Wednesday, July 16, 2025 Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves — insights that could help researchers develop more effective treatment strategies. While ovarian cancer diagnoses and deaths have decreased over recent decades ,

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Monday, May 17, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Larry Norton Elected to the American Academy of Arts & Sciences Larry Norton Larry Norton, MD , Senior Vice President, Office of the President; Medical Director, Evelyn H. Lauder Breast

Discovery reveals that the genetic causes of cancer may be more complicated than previously thought.

… Wednesday, May 27, 2020 Summary It turns out that finding driver mutations may be more complicated than previously thought: Nearly a quarter of all tumors have two different mutations in the same gene. A major effort in cancer research is the search for driver mutations in tumors. These mutations are

The PICI@MSK fellowship will provide Dr. Delconte with two years of financial support for her research on natural killer cells in cancer.

… Wednesday, March 17, 2021 Rebecca Delconte is a postdoctoral fellow working in the lab of immunologist Joseph Sun in the Sloan Kettering Institute. She is the recipient of the 2021-2022 Parker Institute for Cancer Immunotherapy at MSK  Postdoctoral Fellowship, which will provide two years of financial

Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab compared to the control group who did not receive the immune checkpoint inhibitor, according to a new study published today in The New England Journal of Medicine.

… Wednesday, June 18, 2025 Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab compared to the control group who did not receive the immune checkpoint inhibitor,

MSK has developed an arsenal of tests that are at the front lines of precision treatments. They target the structure of proteins that cause cancer, offering people new hope.

… Saturday, July 1, 2023 It was a major milestone a decade in the making. Inside a bustling lab at Memorial Sloan Kettering Cancer Center (MSK) on an otherwise ordinary Thursday in February 2023, specially trained technicians performed a unique test for the 100,000th time. The test was to analyze DNA from

A new study from researchers at MSK and Weill Cornell Medicine provides fresh insights about how cancers evolve when they metastasize — insights that could aid in developing strategies to improve the effectiveness of treatment.

… Monday, June 2, 2025 When cancer spreads from a primary tumor to new sites throughout the body, it undergoes changes that increase its genetic complexity. A new study from researchers at Memorial Sloan Kettering Cancer Center (MSK) and Weill Cornell Medicine provides fresh insights about how cancers

For clinical research stakeholders, implementing and scaling electronic source date (eSource) is a priority. With participation from MSK, a number of Society of Clinical Data Management (SCDM) working groups have collaborated on a paper outlining consensus recommendations on eSource best practices.

… Tuesday, January 13, 2026 For clinical research stakeholders, implementing and scaling electronic source date (eSource) is a priority. With participation from MSK, a number of  Society of Clinical Data Management (SCDM) working groups have collaborated on a paper outlining consensus recommendations on

MSK patients will remain in-network to continue receiving world-class cancer care.

… Tuesday, July 1, 2025 Memorial Sloan Kettering Cancer Center (MSK) and United Healthcare (UHC) today announced a new, multi-year agreement that ensures continued in-network access to MSK for UHC’s commercial members. As a result, current and new UHC-insured patients can continue to receive care at MSK